MSMinoru Satoh

Minoru Satoh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minoru Satoh has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Naoki Kashihara

    Nephrology and Hypertension, Kawasaki Medical School, Kurashiki City Okayama, Japan

    30 shared publications
  • Tamaki Sasaki

    Nephrology and Hypertension, Kawasaki Medical School, Kurashiki City Okayama, Japan

    23 shared publications
  • Hajime Nagasu

    Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan

    11 shared publications
  • Yoshisuke Haruna

    Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan

    9 shared publications
  • Naruya Tomita

    7 shared publications
  • Sohachi Fujimoto

    Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan

    7 shared publications

Latest Publications

  • Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism

    by Minoru Satoh, Tatsuya Maruhashi, Yuichi Yoshida, Hirotaka Shibata

    Primary aldosteronism (PA) is the most common cause of secondary hypertension. The aim of this study was to review the clinical outcomes after mineralocorticoid receptor (MR) antagonist treatment versus adrenalectomy treatment in patients with PA. Relevant medical literature from PubMed, the Cochrane Library, and the ICHUSHI database from 1985 to August 2017 was reviewed. Data extraction was performed independently by three authors. The incidence of cerebrovascular or cardiovascular disease, the improvement of left ventricular hypertrophy or hypokalemia, the severity of hypertension, the incidence of renal dysfunction, and the reduction in the number of oral antihypertensive agents were set as the clinical outcomes. Of the 302 articles selected, 16 were included in the final analysis. Regarding the two therapeutic strategies, no difference in the reduced incidence of cerebrovascular or cardiovascular disease, the prevalence of left ventricular hypertrophy or hypokalemia, or the severity of hypertension, as well as an increase in the incidence of renal dysfunction was observed. Regarding the decrease in the number of oral antihypertensive agents, more agents were reduced in patients who underwent adrenalectomy. Available evidence indicated that the clinical outcomes were not different in PA patients treated with MR antagonist or adrenalectomy, except for a reduction in the number of antihypertensive agents.


  • Open Access

    FP407EVALUATION OF THE GLOMERULAR HEMODYNAMICS BY THE SGLT2 INHIBITOR EMPAGLIFLOZIN USING IN VIVO IMAGING

    by Kengo Kidokoro, Yoshihisa Wada, Megumi Kondo, Yuji Sogawa, Hajime Nagasu, Minoru Satoh, Tamaki Sasaki, Naoki Kashihara

    INTRODUCTION AND AIMS: In the EMPA-REG outcome trial, Empagliflozin (Empa), a sodium-glucose cotransporter 2 inhibitor, slowed the progression of diabetic kidney disease (DKD) in patients with type 2 diabetes. Improvement of glomerular hyperfiltration via tubuloglomerular feedback (TGF) is considered to be one of the possible pathways for renal protection with SGLT2 inhibition (SGLT2i) in diabetic kidney disease (DKD). However, the mechanisms that regulate renal function in response to SGLT2i have not been fully elucidated. We explored the renal protective mechanisms of SGLT2i with empagliflozin (EMPA), with a focus on glomerular hemodynamic effects and TGF using in vivo multiphoton microscope (MPM) imaging techniques.

  • Coping Mechanisms against Oxidative Stress in Kidney Disease

    by Naoki Kashihara, Hajime Nagasu, Minoru Satoh

    慢性腎臓病(chronic kidney disease:CKD)の病態形成には,防御機構を凌駕する活性酸素種産生,すなわち「酸化ストレス」が深く関与している.また,酸化ストレスの亢進には鏡像的変化として,一酸化窒素の生物学的利用能(bioavailability)低下が付随している.このROS/NOの不均衡は,腎臓病の進展のみならず,心血管病の発症機序にも関与している.一方,虚血と酸化ストレスは共存するのが通例であり,また,病因的にも双方向性の関係を有している.虚血の解除は酸化ストレス軽減をもたらし,病態改善につながる.

  • Open Access

    Colchicine attenuates renal fibrosis in a murine unilateral ureteral obstruction model

    by Seiji Itano, Minoru Satoh, Hiroyuki Kadoya, Yuji Sogawa, Atsushi Uchida, Tamaki Sasaki, Naoki Kashihara

    The present study aimed to assess the effects of colchicine, a known anti‑inflammatory agent, on renal fibrosis using a murine model of unilateral ureteral obstruction (UUO). Male C57BL/6 mice were divided into two groups, vehicle‑ and colchicine‑treated. Colchicine (0.5 mg/kg/day) was administered by osmotic pump, and the UUO procedure was performed on the left kidney 7 days later. The mice were sacrificed at 14 days following UUO. Colchicine treatment suppressed interstitial fibrosis of the UUO kidneys. In addition, fibrogenic gene expression in the UUO kidneys was decreased by colchicine administration. NRK‑49F normal rat kidney fibroblasts were cultured with or without colchicine under angiotensin II stimulation, following which a wound‑healing assay and actin fiber staining were performed to evaluate the effects of colchicine in vitro. Colchicine was demonstrated to inhibit angiotensin II‑induced fibroblast migration in vitro in a concentration‑dependent manner. Colchicine treatment also suppressed the angiotensin II‑induced activation of Ras homolog gene family member A in NRK‑49F cells. In conclusion, colchicine treatment significantly inhibited fibroblast activity in vitro and attenuated renal fibrosis in vivo in UUO‑operated mice. Therefore, the prevention of renal fibrosis following injury may represent a novel therapeutic application for colchicine.


  • MP492ENOS/NO SIGNALING ATTENUATES GLOMERULAR INJURY IN DIABETIC MICE VIA SUPPRESSION OF INFLAMMASOME ACTIVATION

    by Yuji Sogawa, Hajime Nagasu, Atsushi Uchida, Seiji Itano, Minoru Satoh, Tamaki Sasaki, Naoki Kashihara

  • Open Access

    Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice

    by Kengo Kidokoro, Minoru Satoh, Seiji Itano, Atsunori Kuwabara, Tamaki Sasaki, Naoki Kashihara

    Introduction: We investigated the feasibility of using a fluorescence resonance energy transfer system to image enzymatic activity in order to evaluate the effects of aliskiren (a direct renin inhibitor) on diabetic nephropathy. Materials and methods: First, we induced diabetes in C57BL/6J mice using streptozotocin, then treated them with either aliskiren (25 mg/kg/day) or the angiotensin type 1 receptor blocker valsartan (15 mg/kg/day) for four weeks. Finally, we utilized renin fluorescence resonance energy transfer substrate to assess renin activity. Results: Renin activity was much higher in the kidneys of diabetic mice compared to those of the non-diabetic control mice. While aliskiren inhibited this activity, valsartan did not. We noted that production of reactive oxygen species intensified and the bioavailability of nitric oxide diminished in the glomeruli of diabetic mice. Aliskiren and valsartan significantly ameliorated these effects. They suppressed glomerular production of reactive oxygen species and urinary albumin excretion. In fact, urinary albumin excretion in diabetic mice treated with aliskiren or valsartan was lower than that in untreated diabetic mice. Furthermore, aliskiren and valsartan significantly reduced glomerular permeability by maintaining the glomerular endothelial surface layer. Conclusion: Fluorescence resonance energy transfer could provide a new tool for evaluating tissue and plasma enzymatic activity.


  • Klotho attenuates renal hypertrophy and glomerular injury in Ins2Akita diabetic mice

    by Hiroyuki Kadoya, Minoru Satoh, Yoshisuke Haruna, Tamaki Sasaki, Naoki Kashihara

    Background Expression of klotho, the renoprotective anti-aging gene, is decreased in diabetic model kidneys. We hypothesized that klotho protein attenuates renal hypertrophy and glomerular injury in a mouse model of diabetic nephropathy. Methods Klotho transgenic (KLTG) mice were crossed with spontaneously diabetic Ins2Akita (AKITA) mice. Glomerular morphology, macrophage infiltration, urinary albumin excretion and urinary 8-hydroxy-2-deoxy guanosine excretion were examined. In vitro, human glomerular endothelial cells were stimulated with high glucose with or without recombinant klotho, and calpain activity and proinflammatory cytokine expressions were measured. Results We found that klotho protein overexpression attenuates renal hypertrophy and glomerular injury in this mouse model of diabetic nephropathy. Klotho overexpression attenuated renal hypertrophy, albuminuria, glomerular mesangial expansion, and endothelial glycocalyx loss in the AKITA mice. AKITA mice exhibit high levels of urinary 8-hydroxy-2-deoxy guanosine excretion. In the presence of klotho overexpression, this effect was reversed. In addition, the glomerular macrophage infiltration characteristic of AKITA mice was attenuated in KLTG-AKITA mice. In human glomerular endothelial cells, high glucose induced calpain activity. This effect was suppressed by expression of recombinant klotho, which also suppressed the induction of proinflammatory cytokines. Conclusion Our data suggest klotho protein protects against diabetic nephropathy through multiple pathways.


  • Open Access

    Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic mice

    by Hajime Nagasu, Minoru Satoh, Emi Kiyokage, Kengo Kidokoro, Kazunori Toida, Keith M Channon, Yashpal S Kanwar, Tamaki Sasaki, Naoki Kashihara


  • Open Access

    Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice

    by Hiroyuki Kadoya, Minoru Satoh, Tamaki Sasaki, Shun'Ichiro Taniguchi, Masafumi Takahashi, Naoki Kashihara

    High levels of aldosterone impair renal function by activating proinflammatory and profibrotic pathways. However, the molecular mechanism underlying aldosterone-induced inflammation and fibrosis is u...